Benzo[b]thiophene-2-sulfonic acid | 92046-18-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: Benzo[b]thiophene-2-sulfonic acid
• 英文别名: 1-benzothiophene-2-sulfonic acid
• CAS: 92046-18-9
• 化学式: C₈H₆O₃S₂
• 分子量: 214.3
• InChiKey: KTVOMLQUDMNZLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  benzo[b]thiophene-2-sulfonic acid (2-amino-phenyl)-amide 、 2-Methoxy-5-(propane-2-sulfonyl)benzenesulfonyl chloride 在 盐酸 、 水 、 Brine 、 Sodium sulfate-III 、 ethyl acetate dichloromethane 作用下， 以 二氯甲烷 、 吡啶 为溶剂， 反应 16.0h， 以to obtain 460 mg of benzo[b]thiophene-2-sulfonic acid {2-[2-methoxy-5-(propane-2 sulfonyl) benzenesulfonylamino]phenyl-amide的产率得到Benzo[b]thiophene-2-sulfonic acid
  参考文献：
  名称：

  Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use

  摘要：

  本发明的实施例提供了一种激动GalR1的双磺酰胺化合物。本发明还提供了包含激动GalR1的双磺酰胺化合物的组合物，以及使用这种化合物和组合物的方法。

  公开号：

  US20090247536A1

文献信息

• [EN] LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME<br/>[FR] LIGANDS DE LA PROTÉINE 2 DE TYPE LANTHIONINE C, CELLULES PRÉPARÉES AVEC CEUX-CI, ET THÉRAPIES LES UTILISANT
  申请人：LANDOS BIOPHARMA INC

  公开号：WO2021127472A1

  公开（公告）日：2021-06-24

  Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including autoimmune diseases, inflammatory diseases, chronic inflammatory diseases, diabetes, and infectious diseases, such as lupus, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, viral diseases, and nonalcoholic steatohepatitis. The compounds can also be used to generate cells, such as immune cells, for treating the conditions.

  提供的是靶向兰硫氨酸合成酶C样蛋白2途径的化合物。这些化合物可用于治疗多种疾病，包括自身免疫性疾病、炎症性疾病、慢性炎症性疾病、糖尿病和传染性疾病，如狼疮、类风湿性关节炎、1型糖尿病、炎症性肠病、病毒性疾病和非酒精性脂肪肝炎。这些化合物还可用于生成细胞，如免疫细胞，以治疗这些疾病。
• Substituted indole sulfonamide compounds their preparation and use as medicaments
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2149573A1

  公开（公告）日：2010-02-03

  The present invention relates to indole sulfonamide compounds of general formula (I), a process for their preparation, a medicament comprising these compounds and the use of the indole sulfonamide compounds for the preparation of medicaments for 5-HT6 receptor regulation as well as for the treatment of disorders related thereto.

  本发明涉及一般式(I)的吲哚磺胺化合物，其制备方法，包含这些化合物的药物以及利用吲哚磺胺化合物制备用于5-HT6受体调节和相关疾病治疗的药物。
• Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
  申请人：Wyeth

  公开号：US20040198778A1

  公开（公告）日：2004-10-07

  Compounds of Formula (I), 1 are provided where T is CHO, CON, or C(OH)R 1 R 2 ; R 1 and R 2 are hydrogen, optionally substituted lower alkyl, CF 3 , optionally substituted alkenyl, or optionally substituted alkynyl; R 3 is hydrogen or optionally substituted lower alkyl; R 4 is (CF 3 ) n alkyl, (CF 3 ) n (substitutedalkyl), (CF 3 ) n alkylphenyl, (CF 3 ) n alkyl(substitutedphenyl), or (F) n cycloalkyl; n=1-3; R 5 is hydrogen, halogen, CF 3 , diene fused to Y when Y═C, or substituted diene fused to Y when Y═C; W, Y and Z are C, CR 6 or N where at least one of W, Y or Z are C; R 6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO 2 , or NR 7 ; R 7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R 8 is lower alkyl, CF 3 , or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.

  提供了具有式(I)的化合物，其中T为CHO、CON或C(OH)R1R2；R1和R2为氢、可选择取代的较低烷基、CF3、可选择取代的烯烃或可选择取代的炔烃；R3为氢或可选择取代的较低烷基；R4为(CF3)n烷基、(CF3)n(取代烷基)、(CF3)n烷基苯基、(CF3)n烷基(取代苯基)或(F)n环烷基；n=1-3；R5为氢、卤素、CF3、与Y融合的双烯烃（当Y为C时）、或与Y融合的取代双烯烃（当Y为C时）；W、Y和Z为C、CR6或N，其中至少有一个为C；R6为氢、卤素或可选择取代的较低烷基；X为O、S、SO2或NR7；R7为氢、可选择取代的较低烷基、可选择取代的苄基或可选择取代的苯基；R8为较低烷基、CF3或可选择取代的苯基。还描述了制备和使用这些化合物来抑制β淀粉样蛋白的产生，以及治疗阿尔茨海默病和唐氏综合征的方法。
• [EN] PLXDC2 LIGANDS<br/>[FR] LIGANDS DE PLXDC2
  申请人：LANDOS BIOPHARMA INC

  公开号：WO2021195360A1

  公开（公告）日：2021-09-30

  Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.

  提供了针对含有plexin结构域2（PLXDC2）的化合物。这些化合物可以用于治疗炎症或免疫介导性疾病、糖尿病、传染病和癌症等疾病。这些化合物可以用于治疗系统性红斑狼疮、类风湿关节炎、多发性硬化症、自身免疫性脑炎、糖尿病肾病、糖尿病视网膜病变、银屑病和炎症性肠病等特定疾病。
• 5-HT7 receptor antagonists
  申请人：Torrens Jover Antoni

  公开号：US20060040978A1

  公开（公告）日：2006-02-23

  The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

  这项发明涉及具有对5-HT7受体具有药理活性的化合物，更特别地涉及一些四氢异喹啉取代磺胺基化合物，以及制备这些化合物的过程，包括含有它们的药物组合物，并且用于治疗和/或预防涉及5-HT的疾病，如中枢神经系统紊乱。